King Pharmaceuticals (KG) Alternative Investment — Quarterly & Annual

Screener

Alternative Investment at other companies

Corebridge FinancialCRBG

$8.18B+0.7%

BlackstoneBX

$1.1B+677%

Assured GuarantyAGO

$928M+0.5%

KG

King PharmaceuticalsKG

$173.28M—

American International GroupAIG

$3.05B-26.6%

iRhythm Holdings, Inc.IRTC

$73.68M—

Other financials

Income statement

Revenue$6.7M+20.1%

Net income-$8.1M-112%

EPS (diluted)-$1.03-107%

Balance sheet

Cash & equivalents$26.3M-43.2%

Total debt$177.0M+0.6%

Total equity$114.0M-24.1%

Total assets$919.6M-20.7%

Cash flow

Operating cash flow-$25.8M-30.0%

Valuation

Market cap$69.71M-73.8%

Enterprise value$220.43M-44.4%

P/E1.4×—

P/S1.6×-30.3×

Profitability

Net margin110.8%—

Returns & leverage

Return on equity37.4%—

Debt / equity1.6×+0.4×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AlternativeInvestment.

The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →

Filed: Aug 7, 2026, 8:49 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-054606

FAQ

What is King Pharmaceuticals's alternative investment?: King Pharmaceuticals (KG) reported alternative investment of $173.28M in Q2 2026.
What does alternative investment mean?: Alternative Investment as reported by Kestrel Group Ltd.

Ask your AI about King Pharmaceuticals's alternative investment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk